The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

“The identification of patients with HR-NMIBC unlikely to respond favorably to intravesical BCG is an unmet need that may facilitate more effective therapy selection and clinical trial enrollment.

There are three types of intravesical immunotherapies for bladder cancer: BCG treatment is the most common immunotherapy for cancer and is often the first-line option for bladder cancer.

Recall that Anktiva plus BCG is one of two intravesical regimens for BCG-unresponsive disease. The other is Adstiladrin, a “non-replicating adenoviral vector-based gene therapy” that was ...

The standard first-line treatment is transurethral resection of the bladder tumor (TURBT) followed by intravesical BCG immunotherapy. However, a significant proportion of patients experience ...

Administered into the bladder via intravesical instillation using ... particularly in patients unresponsive to BCG therapy. The therapy has received FDA Fast Track Designation, reflecting its ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 ...